Attention A T users. To access the menus on this page please perform the following steps. 1. Please switch auto forms mode to off. 2. Hit enter to expand a main menu option (Health, Benefits, etc). 3. To enter and activate the submenu links, hit the down arrow. You will now be able to tab or arrow up or down through the submenu options to access/activate the submenu links.

Multiple Sclerosis Centers of Excellence

Menu
Menu

Quick Links

Veterans Crisis Line Badge
My healthevet badge
EBenefits Badge
Pause Play
MSCOE Newsletter Announcement

MS Veteran Newsletter

Discusses symptom management, medications, and living well with MS. Check out our latest issue!

Learn more »

Get Out and Play

Get Out & Play

Adaptive sports can help keep you in the game. No matter your skill level, there is a sport for you.

Learn more »

People at CMSC Annual Meeting

MSCoE at CMSC Annual Meeting

Learn about presentations, platforms, and posters with VA staff at the MS Centers Annual Meeting!

Learn more »

 

Multiple Sclerosis Centers of Excellence


The Multiple Sclerosis Centers of Excellence are dedicated to furthering the understanding of multiple sclerosis (MS), its impact on Veterans and effective treatments to help manage MS. By partnering with Veterans, caregivers, health care professionals, MS advocates, Veteran service organizations, and community health care institutes, MSCoE strives to minimize impairment and maximize quality of life for Veterans with MS.

MSCoE Network

Announcements

VA MS Publications

map of USMSCoE Network

MSCoE East and West have developed a national network of MS Regional Programs and MS Support Programs within the VA.

Given the size of the population of Veterans with MS seeking treatment in VA and their distribution across the country, it is feasible to provide access to high quality subspecialty care through a hub and spoke network with designated MS Regional Programs supporting local facilities.

Each Veterans Integrated Service Network (VISN) will have at least one MS Regional Program that will serve as a source for MS specialty consultation and education. The primary care for individuals with MS will occur at their local VA medical facilities. MS Support Programs will collaborate with local MS Regional Programs. The MS Care Liaison at VA medical facilities with an MS Support Program will assist with coordination and referrals to the MS Regional Program as needed.

white figure talking through microphoneAnnouncements

June 28, 2018

Based on equivalency data, starting Wednesday, July 25, 2018 VA pharmacy is substituting the generic Mylan 40mg TTW glatiramer acetate with Sandoz Glatopa 40mg TIW and VA pharmacy will begin distributing glatiramer acetate Glatopa to Veterans in both 20mg daily and 40mg TTW dosing formulas. The Glatopa 40mg TTW product requires a new autoinjector.

May 2, 2018

The 8th International Symposium on Gait and Balance is taking place September 15, 2018 in Portland, OR. This conference focuses on the impact and implementation of exercise in MS. The morning focuses on the immunologic, disease modifying, cardiovascular, musculoskeletal, and psychological effects of exercise in MS. The afternoon focuses on clinical applications of exercise in MS and includes presentations on optimizing exercise adherence, high intensity exercise, and exercise prescription. The daytime presentations will be followed by a poster reception, offering the opportunity to discuss new research findings, as well as to network and exchange ideas in a more relaxed social setting.

March 26, 2018

In November 2017, Zostavax was removed from the VA National Formulary and was replaced with Shingrix. Here is a short summary: (1) Shingrix is more effective than Zostavax in preventing cases of herpes zoster (shingles); (2) Shingrix contains an 'adjuvant', boosting vaccine effectiveness and reactions to the vaccine, while Zostavax does not; (3) Shingrix is NOT a live vaccine, unlike Zostavax, which is live; (4) Shingrix does NOT need to be stored frozen while Zostavax needs to be stored in the freezer; (5) Shingrix is given via an intramuscular injection while Zostavax is given via a subcutaneous injection; and (6) Shingrix is given as a two dose series, with doses spaced 2 to 6 months apart while Zostavax is given as a single dose.

Shingrix is not a live vaccine. The efficacy of Shingrix in MS and those on B-cell depleting therapies (rituximab, ocrelizumab) is not known but may be reduced. When possible, complete the Shingrix series prior to starting immunosuppressive or B-cell depleting therapies in people with MS. The safety of Shingrix in MS is not known. Adverse events with Shingrix are listed in the package insert.

FAQ document from VHA PBM
VHA PBM Criteria for Use

March 3, 2018

There is a voluntary withdrawl of daclizumab (Zinbryta®) from the market.


 

Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.

man reading a magazine while sitting at a tableVA MS Publications

The VA ranks as one of the nation’s leaders in health research. Thousands of studies are conducted at VA medical centers, outpatient clinics, and nursing homes each year. This research has significantly contributed to advancements in health care for Veterans and other Americans from every walk of life.

Learn about MSCoE research on our Professionals and Veterans research pages.

Recent VA Provider Publications

Using the Anterior Visual System to Assess Neuroprotection and Remyelination in MS Trials

Headache and Its Management in Patients with MS

Cognitive Impairment in MS

Optical Coherence Tomography Angiography Enhances the Detection of Optic Nerve Damage in MS

Effects of Lipoic Acid on Migration of Human B Cells and Monocyte-enriched Peripheral Blood Mononuclear Cells in Relapsing Remitting MS

Moderators of Treatment Outcomes Following Telehealth Self-Management and Education in Adults with MS: A Secondary Analysis of a Randomized Controlled Trial

A Multicenter Randomized Controlled Trial of Two Group Education Programs for Fatigue in MS: Short- and Medium-term Benefits

Predictors of Mortality in Veterans with MS in an Outpatient Clinic Setting

The Gulf War Era MS Cohort: 3. Early Clinical Features

A Group-delivered Self-management Program Reduces Spasticity in People with MS: A Randomized, Controlled Pilot Trial


Disclaimer: Links are provided as a convenience and for informational purposes only. They do not constitute an endorsement or an approval by MSCoE of any of the products, services, or opinions of the organization. MSCoE bears no responsibility for the accuracy, legality, or content of the external site or for that of subsequent links. Contact the external site for answers to questions regarding its content.